《大行》高盛微升诺诚健华(09969.HK)目标价至19.93元 上季奥布替尼销售稳健

阿斯达克财经
Mar 30

高盛发表研究报告指,诺诚健华(09969.HK) 去年第四季奥布替尼(Orelabrutinib)销售额为3.9亿元人民币,按年增长27%,2025年销售额按年升41%,符合公司之前的指引。由于第四季录得约8.37亿元人民币入账合作收入,公司于2025年录得盈利,较预测提早两年。报告引述管理层指,即使不计入新的业务开发交易,公司仍对2026至2027年度保持盈利充满信心,并强调在达成2025年盈亏...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10